Today, Otonomy Inc. (OTIC) Insider Sold $191,993.75 in Stock

Today, Otonomy Inc. (OTIC) Insider Sold $191,993.75 in Stock
Otonomy Inc. (NASDAQ:OTIC) insider Carl Lebel sold 10,625 shares of the firm’s stock in a transaction on Monday, November 21st. The shares were sold at an average price of $18.07, for a total transaction of $191,993.75. Following the transaction, the insider now directly owns 13,001 shares of the company’s stock, valued at approximately $234,928.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Otonomy Inc. (NASDAQ:OTIC) opened at 18.50 on Friday. Otonomy Inc. has a 52 week low of $10.50 and a 52 week high of $30.75. The company’s market cap is $558.59 million. The company’s 50-day moving average is $16.76 and its 200-day moving average is $15.93.

A number of hedge funds have recently bought and sold shares of OTIC. BlackRock Group LTD raised its stake in Otonomy by 4.0% in the third quarter. BlackRock Group LTD now owns 6,089 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 234 shares during the period. BlackRock Inc. boosted its position in Otonomy by 4.3% in the third quarter. BlackRock Inc. now owns 5,849 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 240 shares in the last quarter. Rhumbline Advisers boosted its position in Otonomy by 1.1% in the third quarter. Rhumbline Advisers now owns 27,179 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 300 shares in the last quarter. Rothschild Asset Management Inc. boosted its position in Otonomy by 2.5% in the third quarter. Rothschild Asset Management Inc. now owns 16,062 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 396 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in Otonomy by 0.8% in the third quarter. California State Teachers Retirement System now owns 50,793 shares of the biopharmaceutical company’s stock worth $924,000 after buying an additional 400 shares in the last quarter. 84.57% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently issued reports on OTIC. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $32.00 price target on shares of Otonomy in a research note on Wednesday, November 2nd. Zacks Investment Research raised shares of Otonomy from a “sell” rating to a “hold” rating in a research note on Wednesday, November 9th.

Otonomy Company Profile

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration.

Receive News & Ratings for Otonomy Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Otonomy Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment